New pill targets rare gene in Hard-to-Treat cancers
NCT ID NCT02122913
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment options left.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
75 people
The number who actually took part.
- Started
-
May 2014
- Finished
-
Apr 2021
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients with a locally advanced or metastatic solid tumor that has progressed or was nonresponsive to available therapies, are unfit for standard chemotherapy or for which no standard or available curative therapy exists * Proof of a malignancy harboring a NTRK fusion * Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 and a life expectancy of at least 3 months * Adequate hematologic, hepatic, and renal function Exclusion Criteria: * Patients with unstable primary central-nervous-system tumors or metastasis, exceptions possible * Clinically significant active cardiovascular disease or history of myocardial infarction * Active uncontrolled systemic bacterial, viral, or fungal infection * Current treatment with a strong CYP3A4 inhibitor or inducer * Pregnancy or lactation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital of the University of Pennsylvania - Radiology
Philadelphia, Pennsylvania, 19104, United States
-
Mass General Cancer Center
Boston, Massachusetts, 02114, United States
-
OHSU Hospital - Neurology
Portland, Oregon, 97239, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center - Texas Medical Center
Houston, Texas, 77030, United States
-
UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
UH Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
UPMC Mercy - Oncology
Pittsburgh, Pennsylvania, 15219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
- New injectable drug tested for safety in Hard-to-Treat solid tumors
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
- Can a new drug shield kidneys from chemotherapy damage?
- Mining Responders' tumors for clues to a universal cancer therapy
- Proton boost radiotherapy aims to hit large tumors harder while sparing healthy tissue